Optimal planning of phase II/III programs for clinical trials with multiple endpoints
From MaRDI portal
Publication:5978237
DOI10.1002/pst.1861WikidataQ53397556 ScholiaQ53397556MaRDI QIDQ5978237
Meinhard Kieser, Heiko Götte, Marietta Kirchner, Eva Dölger
Publication date: 26 April 2018
Published in: Pharmaceutical Statistics (Search for Journal in Brave)
Related Items